Some 20 percent of the human genome is already patented . But a court ruled yesterday that one company does not have the rights to some of its patents on two genes, BRCA1 and BRCA2 , commonly tested for mutations to determine risk for developing breast and ovarian cancer. [More]
District court overturns patents on breast cancer genes
The material in this press release comes from the originating research organization. Content may be edited for style and length. Have a question? Let us know.
Subscribe
One email, each morning, with our latest posts. From medical research to space news. Environment to energy. Technology to physics.
Thank you for subscribing.
Something went wrong.
